Ser1229
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1229  -  BCR-ABL1 (human)

Site Information
AMBIGUOUS SITES: Abl (human):
LDHEPAVsPLLPRKE   SwissProt
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25172818

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 )
Disease tissue studied:
breast cancer ( 4 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
LRRK2-IN-1 ( 3 )

References 

1

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

4

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

5

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info